CN119343343A - 杂环glp-1激动剂 - Google Patents
杂环glp-1激动剂 Download PDFInfo
- Publication number
- CN119343343A CN119343343A CN202380031897.1A CN202380031897A CN119343343A CN 119343343 A CN119343343 A CN 119343343A CN 202380031897 A CN202380031897 A CN 202380031897A CN 119343343 A CN119343343 A CN 119343343A
- Authority
- CN
- China
- Prior art keywords
- alkyl
- cycloalkyl
- optionally substituted
- independently selected
- ring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2022075604 | 2022-02-09 | ||
| CNPCT/CN2022/075604 | 2022-02-09 | ||
| PCT/CN2023/074936 WO2023151574A1 (en) | 2022-02-09 | 2023-02-08 | Heterocyclic glp-1 agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN119343343A true CN119343343A (zh) | 2025-01-21 |
Family
ID=87563618
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202380031897.1A Pending CN119343343A (zh) | 2022-02-09 | 2023-02-08 | 杂环glp-1激动剂 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20250177362A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4476216A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2025506473A (cg-RX-API-DMAC10.html) |
| CN (1) | CN119343343A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2023151574A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021219019A1 (en) | 2020-04-29 | 2021-11-04 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| PE20231181A1 (es) | 2020-08-06 | 2023-08-11 | Gasherbrum Bio Inc | Agonistas del glp-1 heterociclicos |
| SI4408840T1 (sl) | 2021-09-27 | 2025-12-31 | Terns Pharmaceuticals, Inc. | Benzimidazolne karboksilne kisline kot agonisti GLP-1R |
| US12024507B2 (en) | 2021-10-25 | 2024-07-02 | Terns Pharmaceuticals, Inc. | Compounds as GLP-1R agonists |
| JP2025506474A (ja) * | 2022-02-09 | 2025-03-11 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環glp-1アゴニスト |
| AU2023224854A1 (en) | 2022-02-23 | 2024-10-03 | Terns Pharmaceuticals, Inc. | Compounds as glp-1r agonists |
| PE20252787A1 (es) | 2023-04-07 | 2025-12-22 | Terns Pharmaceuticals Inc | Combinacion que comprende un agonista de thr-beta y un agonista de glp-1r para su uso en el tratamiento de un trastorno hepatico o una enfermedad cardiometabolica |
| EP4777197A2 (en) | 2023-09-14 | 2026-07-22 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
| WO2025109387A1 (en) | 2023-11-24 | 2025-05-30 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
| WO2025158275A1 (en) | 2024-01-24 | 2025-07-31 | Pfizer Inc. | Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds |
| WO2025222000A1 (en) * | 2024-04-19 | 2025-10-23 | Eli Lilly And Company | Substituted 1,1'-biphenyl compounds as glucagon receptor agonists |
| TW202606664A (zh) * | 2024-04-19 | 2026-02-16 | 美商美國禮來大藥廠 | 升糖素受體促效劑及其作為療法之用途 |
| WO2026078617A1 (en) * | 2024-10-11 | 2026-04-16 | Pfizer Inc. | Glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190060A1 (ar) * | 2016-09-26 | 2019-03-26 | Chugai Pharmaceutical Co Ltd | مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1 |
| WO2018109607A1 (en) * | 2016-12-16 | 2018-06-21 | Pfizer Inc. | Glp-1 receptor agonists and uses thereof |
| CA3045644C (en) * | 2018-06-13 | 2024-01-16 | Pfizer Inc. | Glp-1 receptor agonists and uses thereof |
| PE20231181A1 (es) * | 2020-08-06 | 2023-08-11 | Gasherbrum Bio Inc | Agonistas del glp-1 heterociclicos |
| JP2025506474A (ja) * | 2022-02-09 | 2025-03-11 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環glp-1アゴニスト |
-
2023
- 2023-02-08 EP EP23752354.3A patent/EP4476216A4/en active Pending
- 2023-02-08 JP JP2024547305A patent/JP2025506473A/ja active Pending
- 2023-02-08 WO PCT/CN2023/074936 patent/WO2023151574A1/en not_active Ceased
- 2023-02-08 CN CN202380031897.1A patent/CN119343343A/zh active Pending
- 2023-02-08 US US18/837,152 patent/US20250177362A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4476216A4 (en) | 2025-12-03 |
| WO2023151574A1 (en) | 2023-08-17 |
| JP2025506473A (ja) | 2025-03-11 |
| US20250177362A1 (en) | 2025-06-05 |
| EP4476216A1 (en) | 2024-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11897851B2 (en) | Heterocyclic GLP-1 agonists | |
| US11926643B2 (en) | Heterocyclic GLP-1 agonists | |
| US20240366639A1 (en) | Heterocyclic glp-1 agonists | |
| CN119137124A (zh) | 杂环glp-1激动剂 | |
| WO2023151574A1 (en) | Heterocyclic glp-1 agonists | |
| US20230165846A1 (en) | Heterocyclic glp-1 agonists | |
| EP4229049A1 (en) | Heterocyclic glp-1 agonists | |
| CN119072474A (zh) | 杂环glp-1激动剂 | |
| WO2023198140A1 (en) | Heterocyclic glp-1 agonists | |
| HK40120672A (en) | Heterocyclic glp-1 agonists | |
| HK40119249A (en) | Heterocyclic glp-1 agonists | |
| HK40083559A (en) | Heterocyclic glp-1 agonists | |
| HK40083559B (en) | Heterocyclic glp-1 agonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40120672 Country of ref document: HK |